Mesoblast Financial Results and Corporate Update Webcast
Mesoblast (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced a webcast to discuss its operational highlights and financial results for the full year ended June 30, 2024. The event is scheduled for Wednesday, August 28 at 6:30pm EDT (Thursday, August 29 at 8:30am AEST). Investors and interested parties can access the webcast through the provided link, with an archived version to be made available on the company's website afterward. This presentation is expected to offer insights into Mesoblast's performance and future outlook in the field of cellular medicines.
Mesoblast (Nasdaq:MESO; ASX:MSB), un leader globale nelle terapie cellulari allogeniche per le malattie infiammatorie, ha annunciato un webcast per discutere i suoi risultati operativi e finanziari per l'intero anno concluso il 30 giugno 2024. L'evento è programmato per mercoledì 28 agosto alle 18:30 EDT (giovedì 29 agosto alle 8:30 AEST). Gli investitori e le parti interessate possono accedere al webcast tramite il link fornito, con una versione archiviata che sarà disponibile successivamente sul sito web dell'azienda. Questa presentazione dovrebbe fornire approfondimenti sulle prestazioni di Mesoblast e sulle prospettive future nel campo delle terapie cellulari.
Mesoblast (Nasdaq:MESO; ASX:MSB), un líder mundial en medicamentos celulares alogénicos para enfermedades inflamatorias, ha anunciado un webcast para discutir sus aspectos operativos y resultados financieros para el año completo que finalizó el 30 de junio de 2024. El evento está programado para miércoles 28 de agosto a las 6:30 p.m. EDT (jueves 29 de agosto a las 8:30 a.m. AEST). Los inversionistas y partes interesadas pueden acceder al webcast a través del enlace proporcionado, con una versión archivada que estará disponible en el sitio web de la empresa después. Se espera que esta presentación ofrezca información sobre el rendimiento de Mesoblast y las perspectivas futuras en el campo de los medicamentos celulares.
Mesoblast (Nasdaq:MESO; ASX:MSB)는 염증 질환을 위한 동종세포 의약품 분야의 세계적 선두주자로서 2024년 6월 30일 종료된 전체 연도의 운영 주요 사항 및 재무 결과를 논의하기 위한 웹캐스트를 발표했습니다. 이 행사는 8월 28일 수요일 오후 6시 30분 EDT (8월 29일 목요일 오전 8시 30분 AEST)로 예정되어 있습니다. 투자자 및 관심 있는 관계자들은 제공된 링크를 통해 웹캐스트에 접속할 수 있으며, 이후 회사 웹사이트에서 아카이브된 버전을 이용할 수 있습니다. 이번 발표는 Mesoblast의 성과와 세포 의약품 분야의 미래 전망에 대한 통찰력을 제공할 것으로 예상됩니다.
Mesoblast (Nasdaq:MESO; ASX:MSB), un acteur mondial de premier plan dans les médicaments cellulaires allogéniques pour les maladies inflammatoires, a annoncé un webinaire pour discuter de ses points saillants opérationnels et de ses résultats financiers pour l'exercice complet se terminant le 30 juin 2024. L'événement est prévu pour le mercredi 28 août à 18h30 EDT (jeudi 29 août à 8h30 AEST). Les investisseurs et parties intéressées peuvent accéder au webinaire via le lien fourni, une version archivée sera disponible sur le site web de l'entreprise par la suite. Cette présentation devrait offrir des perspectives sur la performance de Mesoblast et ses perspectives d'avenir dans le domaine des médicaments cellulaires.
Mesoblast (Nasdaq:MESO; ASX:MSB), ein weltweit führendes Unternehmen im Bereich allogenetischer Zelltherapien für entzündliche Erkrankungen, hat ein Webcast angekündigt, um seine betrieblichen Highlights und finanziellen Ergebnisse für das am 30. Juni 2024 zu Ende gegangene Geschäftsjahr zu diskutieren. Die Veranstaltung ist für Mittwoch, den 28. August um 18:30 Uhr EDT (Donnerstag, den 29. August um 8:30 Uhr AEST) angesetzt. Investoren und interessierte Parteien können über den bereitgestellten Link auf das Webcast zugreifen, wobei eine archivierte Version später auf der Website des Unternehmens verfügbar sein wird. Diese Präsentation wird voraussichtlich Einblicke in die Leistung von Mesoblast und die Zukunftsperspektiven im Bereich der Zelltherapien geben.
- None.
- None.
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2024.
The webcast will begin at 6.30pm EDT, Wednesday, August 28; 8.30am AEST, Thursday, August 29, 2024. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | Media |
| Paul Hughes | BlueDot Media |
| T: +61 3 9639 6036 | Steve Dabkowski |
| E: investors@mesoblast.com | T: +61 419 880 486 |
| E: steve@bluedot.net.au |
FAQ
When is Mesoblast's financial results webcast for the full year ended June 30, 2024?
How can investors access Mesoblast's (MESO) financial results webcast?
What will be discussed in Mesoblast's (MESO) upcoming webcast?
Where can I find the archived version of Mesoblast's (MESO) financial results webcast?
